tiprankstipranks
Definium Therapeutics, Inc. (DE:MMQ0)
NASDAQ:MMQ0
Germany Market
MMQ0
Definium Therapeutics
RESEARCH TOOLSreports

Definium Therapeutics (MMQ0) Stock Forecast & Price Target

12 Followers
See the Price Targets and Ratings of:

MMQ0 Analyst Ratings

Strong Buy
15Ratings
Strong Buy
15 Buy
0 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Definium
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MMQ0 Stock 12 Month Forecast

Average Price Target

€57.33
▲(50.87% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Definium Therapeutics in the last 3 months. The average price target is €57.33 with a high forecast of €77.16 and a low forecast of €45.44. The average price target represents a 50.87% change from the last price of €38.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","24":"€24","42":"€42","60":"€60","78":"€78"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":77.1633387,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€77.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.32950275266667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€57.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.44063279,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€45.44</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,24,42,60,78],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.5,40.55102605384615,43.60205210769231,46.65307816153846,49.70410421538462,52.75513026923077,55.80615632307692,58.85718237692308,61.90820843076923,64.95923448461538,68.01026053846154,71.06128659230768,74.11231264615384,{"y":77.1633387,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.5,39.02534636558974,40.55069273117949,42.07603909676923,43.60138546235898,45.12673182794872,46.652078193538465,48.177424559128205,49.70277092471795,51.228117290307694,52.75346365589744,54.27881002148718,55.80415638707693,{"y":57.32950275266667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.5,38.110817906923074,38.721635813846156,39.33245372076923,39.94327162769231,40.554089534615386,41.16490744153846,41.77572534846154,42.386543255384616,42.9973611623077,43.60817906923077,44.218996976153846,44.82981488307693,{"y":45.44063279,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.65,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€77.16Average Price Target€57.33Lowest Price Target€45.44
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:MMQ0
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€0.86→€64.3
Buy
69.22%
Upside
Initiated
08/18/26
Definium Therapeutics initiated with a Buy at BofADefinium Therapeutics initiated with a Buy at BofA
Piper Sandler Analyst forecast on DE:MMQ0
David Amsellem
Piper Sandler
Piper Sandler
€64.3
Buy
69.22%
Upside
Reiterated
08/17/26
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Immuneering (IMRX)
H.C. Wainwright Analyst forecast on DE:MMQ0
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€60.02
Buy
57.94%
Upside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Tenax Therapeutics (NASDAQ: TENX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
Jefferies Analyst forecast on DE:MMQ0
Andrew Tsai
Jefferies
Jefferies
€55.73
Buy
46.66%
Upside
Reiterated
08/13/26
Analysts' Top Healthcare Picks: MaxCyte (MXCT), Definium Therapeutics (DFTX)
JonesTrading Analyst forecast on DE:MMQ0
Justin Walsh
JonesTrading
JonesTrading
€63.45→€77.16
Buy
103.06%
Upside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Olympus (Other OTC: OCPNF), Journey Medical Corp (NASDAQ: DERM) and Definium Therapeutics (NASDAQ: DFTX)
Canaccord Genuity Analyst forecast on DE:MMQ0
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€49.73→€54.87
Buy
44.40%
Upside
Reiterated
08/13/26
Canaccord Genuity Remains a Buy on Definium Therapeutics (DFTX)
Wells Fargo Analyst forecast on DE:MMQ0
Benjamin Burnett
Wells Fargo
Wells Fargo
€58.3→€61.73
Buy
62.45%
Upside
Reiterated
08/13/26
Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo
Maxim Group Analyst forecast on DE:MMQ0
Michael Okunewitch
Maxim Group
Maxim Group
€42.87→€47.16
Buy
24.09%
Upside
Assigned
08/13/26
Analysts Conflicted on These Healthcare Names: Definium Therapeutics (NASDAQ: DFTX), Ionis Pharmaceuticals (NASDAQ: IONS) and Sutro Biopharma (NASDAQ: STRO)
Needham Analyst forecast on DE:MMQ0
Ami Fadia
Needham
Needham
€42.87→€56.59
Buy
48.91%
Upside
Reiterated
08/12/26
Ami Fadia Reiterates Buy on Definium (DFTX) as Strong Phase 3 VOYAGE Data Support Unchanged $50 Price Target
RBC Capital Analyst forecast on DE:MMQ0
Brian Abrahams
RBC Capital
RBC Capital
€48.87→€56.59
Buy
48.91%
Upside
Assigned
08/12/26
RBC Capital Sticks to Their Buy Rating for Definium Therapeutics (DFTX)
LifeSci Capital Analyst forecast on DE:MMQ0
Francois Brisebois
LifeSci Capital
LifeSci Capital
€54.01→€64.3
Buy
69.22%
Upside
Reiterated
08/12/26
Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Eli Lilly & Co (LLY)
Evercore ISI Analyst forecast on DE:MMQ0
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
€45.44
Buy
19.58%
Upside
Reiterated
08/10/26
Evercore ISI Sticks to Its Buy Rating for Definium Therapeutics (DFTX)
Oppenheimer Analyst forecast on DE:MMQ0
Jay Olson
Oppenheimer
Oppenheimer
€51.44
Buy
35.37%
Upside
Reiterated
08/07/26
Definium Therapeutics (DFTX) Receives a Buy from Oppenheimer
Stifel Nicolaus Analyst forecast on DE:MMQ0
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€51.44
Buy
35.37%
Upside
Reiterated
08/07/26
Definium Therapeutics (DFTX) Gets a Buy from Stifel Nicolaus
Robert W. Baird Analyst forecast on DE:MMQ0
Christopher Chen
Robert W. Baird
Robert W. Baird
€31.72→€48.87
Buy
28.61%
Upside
Reiterated
06/23/26
Definium Therapeutics price target raised to $57 from $37 at BairdDefinium Therapeutics price target raised to $57 from $37 at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:MMQ0
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
€0.86→€64.3
Buy
69.22%
Upside
Initiated
08/18/26
Definium Therapeutics initiated with a Buy at BofADefinium Therapeutics initiated with a Buy at BofA
Piper Sandler Analyst forecast on DE:MMQ0
David Amsellem
Piper Sandler
Piper Sandler
€64.3
Buy
69.22%
Upside
Reiterated
08/17/26
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Immuneering (IMRX)
H.C. Wainwright Analyst forecast on DE:MMQ0
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
€60.02
Buy
57.94%
Upside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Tenax Therapeutics (NASDAQ: TENX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
Jefferies Analyst forecast on DE:MMQ0
Andrew Tsai
Jefferies
Jefferies
€55.73
Buy
46.66%
Upside
Reiterated
08/13/26
Analysts' Top Healthcare Picks: MaxCyte (MXCT), Definium Therapeutics (DFTX)
JonesTrading Analyst forecast on DE:MMQ0
Justin Walsh
JonesTrading
JonesTrading
€63.45→€77.16
Buy
103.06%
Upside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Olympus (Other OTC: OCPNF), Journey Medical Corp (NASDAQ: DERM) and Definium Therapeutics (NASDAQ: DFTX)
Canaccord Genuity Analyst forecast on DE:MMQ0
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€49.73→€54.87
Buy
44.40%
Upside
Reiterated
08/13/26
Canaccord Genuity Remains a Buy on Definium Therapeutics (DFTX)
Wells Fargo Analyst forecast on DE:MMQ0
Benjamin Burnett
Wells Fargo
Wells Fargo
€58.3→€61.73
Buy
62.45%
Upside
Reiterated
08/13/26
Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo
Maxim Group Analyst forecast on DE:MMQ0
Michael Okunewitch
Maxim Group
Maxim Group
€42.87→€47.16
Buy
24.09%
Upside
Assigned
08/13/26
Analysts Conflicted on These Healthcare Names: Definium Therapeutics (NASDAQ: DFTX), Ionis Pharmaceuticals (NASDAQ: IONS) and Sutro Biopharma (NASDAQ: STRO)
Needham Analyst forecast on DE:MMQ0
Ami Fadia
Needham
Needham
€42.87→€56.59
Buy
48.91%
Upside
Reiterated
08/12/26
Ami Fadia Reiterates Buy on Definium (DFTX) as Strong Phase 3 VOYAGE Data Support Unchanged $50 Price Target
RBC Capital Analyst forecast on DE:MMQ0
Brian Abrahams
RBC Capital
RBC Capital
€48.87→€56.59
Buy
48.91%
Upside
Assigned
08/12/26
RBC Capital Sticks to Their Buy Rating for Definium Therapeutics (DFTX)
LifeSci Capital Analyst forecast on DE:MMQ0
Francois Brisebois
LifeSci Capital
LifeSci Capital
€54.01→€64.3
Buy
69.22%
Upside
Reiterated
08/12/26
Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Eli Lilly & Co (LLY)
Evercore ISI Analyst forecast on DE:MMQ0
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
€45.44
Buy
19.58%
Upside
Reiterated
08/10/26
Evercore ISI Sticks to Its Buy Rating for Definium Therapeutics (DFTX)
Oppenheimer Analyst forecast on DE:MMQ0
Jay Olson
Oppenheimer
Oppenheimer
€51.44
Buy
35.37%
Upside
Reiterated
08/07/26
Definium Therapeutics (DFTX) Receives a Buy from Oppenheimer
Stifel Nicolaus Analyst forecast on DE:MMQ0
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€51.44
Buy
35.37%
Upside
Reiterated
08/07/26
Definium Therapeutics (DFTX) Gets a Buy from Stifel Nicolaus
Robert W. Baird Analyst forecast on DE:MMQ0
Christopher Chen
Robert W. Baird
Robert W. Baird
€31.72→€48.87
Buy
28.61%
Upside
Reiterated
06/23/26
Definium Therapeutics price target raised to $57 from $37 at BairdDefinium Therapeutics price target raised to $57 from $37 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Definium Therapeutics

3 Months
Sumant KulkarniCanaccord Genuity
Success Rate
11/14 ratings generated profit
79%
Average Return
+39.06%
Copying Sumant Kulkarni's trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +39.06% per trade.
1 Year
Patrick TrucchioH.C. Wainwright
Success Rate
15/18 ratings generated profit
83%
Average Return
+130.88%
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +130.88% per trade.
2 Years
Brian AbrahamsRBC Capital
Success Rate
18/19 ratings generated profit
95%
Average Return
+218.69%
Copying Brian Abrahams's trades and holding each position for 2 Years would result in 94.74% of your transactions generating a profit, with an average return of +218.69% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MMQ0 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
25
31
36
22
21
Buy
6
4
11
9
20
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
35
47
31
41
In the current month, MMQ0 has received 41 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MMQ0 average Analyst price target in the past 3 months is 57.33.
Each month's total comprises the sum of three months' worth of ratings.

MMQ0 Financial Forecast

MMQ0 Earnings Forecast

Next quarter’s earnings estimate for MMQ0 is -€0.48 with a range of -€0.60 to -€0.39. The previous quarter’s EPS was -€1.24. MMQ0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year MMQ0 has Performed in-line its overall industry.
Next quarter’s earnings estimate for MMQ0 is -€0.48 with a range of -€0.60 to -€0.39. The previous quarter’s EPS was -€1.24. MMQ0 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year MMQ0 has Performed in-line its overall industry.
No data currently available

MMQ0 Sales Forecast

Next quarter’s sales forecast for MMQ0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. MMQ0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year MMQ0 has Performed in-line its overall industry.
Next quarter’s sales forecast for MMQ0 is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. MMQ0 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year MMQ0 has Performed in-line its overall industry.

MMQ0 Stock Forecast FAQ

What is DE:MMQ0’s average 12-month price target, according to analysts?
Based on analyst ratings, Definium Therapeutics, Inc.’s 12-month average price target is 57.33.
    What is DE:MMQ0’s upside potential, based on the analysts’ average price target?
    Definium Therapeutics, Inc. has 50.87% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Definium Therapeutics, Inc. a Buy, Sell or Hold?
          Definium Therapeutics, Inc. has a consensus rating of Strong Buy, which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Definium Therapeutics, Inc.’s share price target?
            The average share price target for Definium Therapeutics, Inc. is 57.33. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €77.16 ,and the lowest forecast is €45.44. The average share price target represents 50.87% Increase from the current price of €38.
              What do analysts say about Definium Therapeutics, Inc.?
              Definium Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of Definium Therapeutics, Inc.?
                To buy shares of DE:MMQ0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.